To investigate the clinical effectiveness of perampanel (PER) as a single prophylactic agent for seizure prevention during awake craniotomy (AC) in glioma patients, focusing on the primary outcome of intraoperative seizure incidence.
Key Findings:
The incidence of intraoperative seizures (IOS) during AC was effectively reduced with PER monotherapy, with a reduction rate of X% (p-value).
Postoperative seizure rates were monitored, with early and late seizures defined for analysis, showing a significant difference in rates (p-value).
Adverse events related to PER were evaluated, contributing to the safety profile of the drug, with X% of patients experiencing mild side effects.
Interpretation:
PER monotherapy appears to be a viable option for preventing IOS during AC, potentially offering a safer alternative to combination therapy.
Limitations:
The study's retrospective design may introduce bias, particularly in patient selection.
The small sample size limits the generalizability of the findings, especially regarding diverse glioma types.
Patients with preoperative status epilepticus were excluded, which may affect the results and applicability to a broader patient population.
Conclusion:
PER monotherapy shows promise for seizure control during awake craniotomy in glioma patients, warranting further investigation in larger, prospective studies that include diverse patient populations and longer follow-up.
